Key clinical point: Orelabrutinib, a novel Bruton tyrosine kinase inhibitor, appears safe and effective in patients with relapsed or refractory mantle cell lymphoma.
Major finding: Orelabrutinib produced an overall response rate of 86% and a 12-month progression-free survival rate of 64%.
Study details: A phase 2 trial of 106 patients with relapsed/refractory mantle cell lymphoma.
Disclosures: The study was sponsored by InnoCare Pharma. Dr. Deng reported having no conflicts of interest.
Deng L et al. ASH 2019, Abstract 755.